Bars

Category: Suggested Reading

All Podcast Categories
S4-40.1 - Liver as a Regenerative Organ and the Use and Limitations of NITs

S4-40.1 – Liver as a Regenerative Organ and the Use and Limitations of NITs

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.

September 16, 2023
S2-5 - Key Insights from the American Diabetes Association 83rd Scientific Sessions

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

July 13, 2023
S4-27.3 - Abstract session - NAFLD: Clinical Aspects

S4-27.3 – Abstract session – NAFLD: Clinical Aspects

This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.

June 17, 2023
S4-25.5 - Wrap-Up on NICE Guidance for FibroScan

S4-25.5 – Wrap-Up on NICE Guidance for FibroScan

William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This final conversation addresses a closing question around the future of FibroScan and how NICE will have progressed on the issue over the next 18 months.

June 12, 2023
S4-25.4 - NICE Guidance for FibroScan: The Devil is in the Details

S4-25.4 – NICE Guidance for FibroScan: The Devil is in the Details

William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation offers stimulating ideas around best ways to implement community screening.

June 12, 2023
S4-25.2 - NICE Guidance for FibroScan: Collecting Data Well and Wisely

S4-25.2 – NICE Guidance for FibroScan: Collecting Data Well and Wisely

William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation speculates on the value and accuracy of FAST and other tests. The group considers the importance of collecting data and what impact the guidance and experience in the UK will have for onlooking systems.

June 12, 2023
S4-E25.1 - Meeting Vanessa Hebditch and the Role of the British Liver Trust in Fighting for FibroScan

S4-E25.1 – Meeting Vanessa Hebditch and the Role of the British Liver Trust in Fighting for FibroScan

William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation focuses on the role of the British Liver Trust in this process and the importance of data collection for quality assurance.

June 12, 2023
S4-23.1 - Obeticholic Acid: Is the Juice Worth the Squeeze?

S4-23.1 – Obeticholic Acid: Is the Juice Worth the Squeeze?

Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. This conversation features Stephen’s take on the recent outcome of the FDA ADCOM meeting for obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH.

May 31, 2023
S4-22 - PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

S4-22 – PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.

May 22, 2023

Listen Now

Apple Spotify Youtube
Copyright © SurfingNASH.Com 2020—2023
Linkedin Facebook Twitter Instagram
Apple Spotify Youtube Soundcloud
More Episodes
Log In
Stay In Touch
Apple Spotify Youtube

Experience Nudge Learning! Interested in a new way of learning?

Learn More About CME